Abzena, a contract manufacturer of biologics and antibody drug conjugates, has invested $60 million in a new facility in San Diego, California for late-phase and commercial manufacturing.

The new facility is approximately 50,000 square feet and houses a 7,400-square-foot process process-development laboratory and two new manufacturing cleanrooms at the 500-L and 2,000-L scale using single-use bioreactors. The facility also houses a GMP warehouse and analytical development and quality control laboratories. It provides Phase I to commercial manufacturing for biologics projects.

The addition of the new facility has a created 125 new positions within the company. The new facility in San Diego mirrors the company’s bioconjugation facility in Bristol, Pennsylvania, which supports bioconjugation from Phase I into commercial manufacturing.

Source: Abzena